1. Top
  2. Business Overview
  3. In-house projects

In-house projects

In-house projects with collaboration opportunity are summarized in the following table:

Target (domain) Modality Partner Status
TNF-α (immunology)1) Small molecule None Lead generation stage
Runx1-CBFβ
(hematology)
Small molecule Yokohama City Univ. Hit validation stage
IL-6 (immunology)2) Small molecule Hirosaki Univ. Lead generation stage
TIM-3 (oncology; immune checkpoint)3) HLHP None Hit/lead identification stage
Amyloid β (C99)
(Alzheimer disease)
HLHP Doshisha Univ. Hit/lead identification stage
Smurf1 [E3 ligase]
(CV; PAH)
Small molecule New York Medical Coll. Hit validation stage
NKG2A (oncology; immune checkpoint)4) HLHP None Hit/lead identification stage
Tubulin (oncology) Small molecule None Lead generation stage
Tumor angiogenesis inhibitor Small molecule None Lead optimization stage
Notch1 (oncology, GI) Small molecule None Lead generation stage
SARS-CoV-2 (virology) Small molecule None Drug repurposing (on-going)5)
Drug discovery (planned)
6)

Summary of nonconfidential information on each project of 1)- 6) is disclosed in the separated PDF sheet.